Benitec Biopharma Files 2024 Proxy Statement
Ticker: BNTC · Form: DEF 14A · Filed: Oct 22, 2024 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | DEF 14A |
| Filed Date | Oct 22, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $0.0017, $1.93, $3.86 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, regulatory-filing
TL;DR
Benitec Biopharma's DEF 14A is out for the Dec 4th shareholder meeting. Vote your shares!
AI Summary
Benitec Biopharma Inc. filed its definitive proxy statement (DEF 14A) on October 23, 2024, for its 2024 Annual Meeting of Stockholders scheduled for December 4, 2024. The filing, located at 3940 Trust Way, Hayward, CA 94545, details the information required for the proxy statement under Section 14(a) of the Securities Exchange Act of 1934.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming annual meeting, enabling them to make informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would typically indicate risk.
Key Numbers
- 2024 — Annual Meeting Year (The filing pertains to the 2024 Annual Meeting of Stockholders.)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- October 23, 2024 (date) — Filing Date
- December 4, 2024 (date) — Annual Meeting Date
- 3940 Trust Way, Hayward, CA 94545 (address) — Company Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxy votes from shareholders for an upcoming meeting, providing detailed information about matters to be voted upon.
When is the 2024 Annual Meeting of Stockholders for Benitec Biopharma Inc.?
The 2024 Annual Meeting of Stockholders for Benitec Biopharma Inc. is scheduled for December 4, 2024.
What is the filing date of this DEF 14A for Benitec Biopharma Inc.?
The definitive proxy statement (DEF 14A) for Benitec Biopharma Inc. was filed on October 23, 2024.
Where is Benitec Biopharma Inc. located?
Benitec Biopharma Inc. is located at 3940 Trust Way, Hayward, California 94545.
Under which section of the Securities Exchange Act is this filing made?
This filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Filing Stats: 4,732 words · 19 min read · ~16 pages · Grade level 13.4 · Accepted 2024-10-23 09:23:39
Key Financial Figures
- $0.0001 — 00 shares of preferred stock, par value $0.0001 per share, and to make a corresponding
- $0.0017 — rcise price 5 Table of Contents of $0.0017 per share, subject to the limitations o
- $1.93 — of Common Stock at an exercise price of $1.93 per share, (ii) Pre-Funded Warrants exe
- $3.86 — of Common Stock at an exercise price of $3.86 per share, subject to the limitations o
Filing Documents
- d838871ddef14a.htm (DEF 14A) — 326KB
- g838871g10a01.jpg (GRAPHIC) — 36KB
- g838871g10a02.jpg (GRAPHIC) — 2KB
- g838871g10a03.jpg (GRAPHIC) — 11KB
- g838871g10a04.jpg (GRAPHIC) — 2KB
- g838871g10a05.jpg (GRAPHIC) — 2KB
- g838871g10a06.jpg (GRAPHIC) — 4KB
- g838871g10a08.jpg (GRAPHIC) — 3KB
- g838871g10a09.jpg (GRAPHIC) — 12KB
- g838871g10a10.jpg (GRAPHIC) — 11KB
- g838871g10t14.jpg (GRAPHIC) — 15KB
- g838871g36w34.jpg (GRAPHIC) — 29KB
- g838871g59c16.jpg (GRAPHIC) — 28KB
- 0001193125-24-241155.txt ( ) — 538KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 15 Summary Compensation Table 15 Narrative Disclosure to Summary Compensation Table 16 Outstanding Equity Awards at Fiscal Year-End 18 Other Elements of Compensation 19 Pay Versus Performance Disclosure 19 Relationship Between Financial Performance Measures and CAP 21 DIRECTOR COMPENSATION 22 Narrative Disclosure to Director Compensation Table 22 PROPOSAL 1ELECTION OF DIRECTORS 24 Required Vote 24 i Table of Contents Page PROPOSAL 2RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 25 Required Vote 25 AUDIT COMMITTEE REPORT 27 PROPOSAL 3ADVISORY VOTE ON EXECUTIVE COMPENSATION 28 Required Vote 28 PROPOSAL 4APPROVAL OF AN AMENDMENT TO THE COMPANYS CERTIFICATE OF INCORPORATION TO AUTHORIZE THE ISSUANCE OF UP TO 5,000,000 SHARES OF PREFERRED STOCK 29 Required Vote 30 ANNUAL REPORT TO STOCKHOLDERS 31 OTHER MATTERS 31 DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS 31 Appendix AAmendment if Proposal 4 is approved by the Stockholders at the Annual Meeting A-1 ii Table of Contents 3940 Trust Way Hayward, California 94545 2024 ANNUAL MEETING PROXY STATEMENT We are making these proxy materials available to you in connection with the solicitation of proxies by the Board of Directors (the Board) of Benitec Biopharma Inc. for the 2024 Annual Meeting of Stockholders (the Annual Meeting) to be held virtually on December 4, 2024 at 1:00 p.m., Pacific Time, and for any adjournment or postponement of the Annual Meeting. The Annual Meeting can be accessed by visiting www.meetnow.global/MXPAUVL, where you will be able to listen to the meeting live, submit questions, and vote online. The mailing of the Notice of Internet Availability of Proxy Materials and the Proxy Statement and Annual Report will commence on or about October 22, 2024. Electronic copies of this Proxy Statement and the Annual Report for the year ended June 30,